Petrelintide — Safety, Research, Risks & Legal Status

Not medical advice. Petrelintide is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	ZP8396
Category	Peptide (research chemical)
Developer	Zealand Pharma (originator) with Roche/Genentech as co-development partner since March 2025
Development code	ZP8396
Estimated half-life	Approximately 10 days (preclinical estimate); supports once-weekly subcutaneous dosing
Phase 2b weight loss (ZUPREME-1)	10.7% mean weight loss at 42 weeks vs. 1.7% placebo at highest evaluated dose
GI tolerability vs. GLP-1 agents	Nausea ~19.6% (vs. ~40-50% for GLP-1 agents); zero vomiting at highest dose in Phase 2b
Phase 3 status	Planned initiation H2 2026 for chronic weight management; no Phase 3 data available as of mid-2026
US legal status	Investigational drug only. Not approved by the FDA, EMA, or any other regulatory authority as of mid-2026. No marketing authorization exists in any jurisdiction. Not for human consumption outside of authorized clinical trials. Classified as an unapproved investigational new drug (IND) under US law.

What is Petrelintide?

Petrelintide (ZP8396) is a long-acting, acylated synthetic analog of human amylin under clinical development by Zealand Pharma in partnership with Roche/Genentech for the treatment of obesity and overweight. It is a 36-amino-acid peptide engineered for once-weekly subcutaneous injection, distinguished from GLP-1 receptor agonists by its primary mechanism acting on amylin and calcitonin receptors rather than the GLP-1 pathway. As of mid-2026, it has completed Phase 2b trials and is advancing toward Phase 3 initiation for chronic weight management.

How it works

Petrelintide is a selective amylin receptor agonist that mimics the endogenous pancreatic hormone amylin. It activates both amylin receptors (AMY1-3, which are heterodimers of calcitonin receptor plus receptor activity-modifying proteins) and calcitonin receptors (CTR). The proposed mechanism centers on restoration of central leptin sensitivity - amylin is believed to act synergistically with leptin in the hypothalamus to suppress appetite and induce early satiation, a pathway impaired in obesity. By restoring this signaling, petrelintide reduces food intake without the pronounced nausea and vomiting associated with GLP-1 receptor agonism. Structural stability is achieved through lactam bridge stabilization and N-terminal fatty diacid acylation, extending the estimated half-life to approximately 10 days and sustaining plasma concentrations for up to 168 hours post-dose in preclinical models.

Background & history

Amylin as a therapeutic target has precedent in pramlintide (Symlin), an FDA-approved short-acting amylin analog approved in 2005 as an adjunct to insulin in type 1 and type 2 diabetes, though pramlintide requires multiple daily injections and achieved only modest weight loss. Zealand Pharma pursued a long-acting amylin analog to address the pharmacokinetic limitations of pramlintide, developing ZP8396 with acylation and lactam bridge chemistry to allow once-weekly dosing. In March 2025, Zealand Pharma announced a co-development and co-commercialization agreement with Roche/Genentech, with petrelintide intended partly as a combination partner for Roche's GLP-1/GIP dual agonist CT-388. Phase 2b results announced in early 2026 (ZUPREME-1) showed clinically meaningful weight loss with a tolerability profile notably differentiated from GLP-1 agents. Phase 3 initiation was announced for the second half of 2026.

What the research says

Phase 2b data from ZUPREME-1 (NCT06662539) - a 42-week trial in adults with obesity or overweight without type 2 diabetes - demonstrated 10.7% mean placebo-adjusted weight loss at the highest evaluated dose, meeting the trial's primary endpoint. The ZUPREME-2 trial (NCT06926842) enrolled participants with type 2 diabetes over 28 weeks. Preclinical rodent studies reported significant cumulative reductions in food intake and body weight at doses of 1-15 nmol/kg with single and repeated dosing. The gastrointestinal adverse event profile in ZUPREME-1 was notably lower than typically reported with GLP-1 receptor agonists: nausea occurred in approximately 19.6% of petrelintide-treated subjects versus 6.2% placebo, compared to the roughly 40-50% nausea rates commonly observed with GLP-1 agents; vomiting was 3% versus 6.2% placebo with zero vomiting events at the highest effective dose. The GI-related discontinuation rate was 1.5%. No serious safety signals were identified in reported Phase 2b data. Long-term efficacy, cardiovascular outcomes, durability of weight loss after discontinuation, and head-to-head comparisons with GLP-1 agents remain to be established in Phase 3.

Reported effects

Reduction in body weight - mean 10.7% at 42 weeks in Phase 2b (ZUPREME-1), compared to 1.7% placebo
Reduction in food intake via induction of early satiation and appetite suppression, proposed to operate through amylin and leptin signaling pathways
Activation of amylin receptors (AMY1-3) and calcitonin receptors in the central nervous system
Potential improvement in metabolic parameters in obesity and type 2 diabetes populations (ZUPREME-2 results pending full publication as of mid-2026)
Effects on leptin sensitivity restoration are mechanistically proposed but not yet directly demonstrated in human trials
No direct comparison to GLP-1 agents in head-to-head trials; indirect evidence suggests differentiated GI tolerability profile

Dosing & administration (informational)

In Phase 2b trials, petrelintide was administered as a once-weekly subcutaneous injection at neutral pH. The specific dose levels evaluated in ZUPREME-1 have not been fully disclosed in publicly available summaries as of mid-2026. Published preclinical studies used dose ranges of 1-15 nmol/kg in rodents. This information is provided for scientific reference only and does not constitute a dosing protocol. Petrelintide is not approved for use, and anyone with clinical interest in amylin-pathway therapies should consult a licensed clinician. No self-administration guidance is appropriate for an unapproved investigational compound.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Nausea reported in ~19.6% of subjects in ZUPREME-1 Phase 2b versus 6.2% placebo - lower than typical GLP-1 agent rates but still above placebo
Vomiting: ~3% petrelintide versus ~6.2% placebo; zero vomiting at maximum evaluated dose in ZUPREME-1
GI-related discontinuation rate of 1.5% in Phase 2b
No serious safety signals or treatment-related discontinuations due to vomiting reported in Phase 2b data available as of mid-2026
Long-term safety (beyond 42 weeks), rare adverse events, and safety in special populations have not been established - Phase 3 data are required
Calcitonin receptor agonism raises theoretical considerations given calcitonin receptor distribution in bone and thyroid; the clinical significance in humans at therapeutic doses has not been fully characterized in published literature
Not approved for human use; use outside clinical trials is unsupported by any regulatory framework

Drug & supplement interactions

N
o
h
u
m
a
n
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
f
o
r
p
e
t
r
e
l
i
n
t
i
d
e
h
a
v
e
b
e
e
n
p
u
b
l
i
s
h
e
d
a
s
o
f
m
i
d
-
2
0
2
6
.
M
e
c
h
a
n
i
s
t
i
c
c
o
n
s
i
d
e
r
a
t
i
o
n
s
i
n
c
l
u
d
e
p
o
t
e
n
t
i
a
l
a
d
d
i
t
i
v
e
o
r
s
y
n
e
r
g
i
s
t
i
c
e
f
f
e
c
t
s
w
i
t
h
G
L
P
-
1
r
e
c
e
p
t
o
r
a
g
o
n
i
s
t
s
(
t
h
e
i
n
t
e
n
d
e
d
c
o
m
b
i
n
a
t
i
o
n
s
t
r
a
t
e
g
y
w
i
t
h
R
o
c
h
e
'
s
C
T
-
3
8
8
i
s
u
n
d
e
r
a
c
t
i
v
e
i
n
v
e
s
t
i
g
a
t
i
o
n
)
,
a
n
d
p
o
s
s
i
b
l
e
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
i
n
s
u
l
i
n
o
r
o
t
h
e
r
g
l
u
c
o
s
e
-
l
o
w
e
r
i
n
g
a
g
e
n
t
s
i
n
d
i
a
b
e
t
i
c
p
o
p
u
l
a
t
i
o
n
s
(
r
e
l
e
v
a
n
t
g
i
v
e
n
Z
U
P
R
E
M
E
-
2
e
n
r
o
l
l
m
e
n
t
)
.
P
r
a
m
l
i
n
t
i
d
e
(
a
n
a
p
p
r
o
v
e
d
s
h
o
r
t
-
a
c
t
i
n
g
a
m
y
l
i
n
a
n
a
l
o
g
)
l
a
b
e
l
i
n
g
n
o
t
e
s
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
d
r
u
g
s
t
h
a
t
a
l
t
e
r
G
I
m
o
t
i
l
i
t
y
a
n
d
d
r
u
g
s
r
e
q
u
i
r
i
n
g
r
a
p
i
d
G
I
a
b
s
o
r
p
t
i
o
n
(
e
.
g
.
,
o
r
a
l
a
n
a
l
g
e
s
i
c
s
,
a
n
t
i
b
i
o
t
i
c
s
)
-
w
h
e
t
h
e
r
t
h
e
s
e
c
o
n
s
i
d
e
r
a
t
i
o
n
s
e
x
t
e
n
d
t
o
p
e
t
r
e
l
i
n
t
i
d
e
a
t
o
n
c
e
-
w
e
e
k
l
y
d
o
s
i
n
g
h
a
s
n
o
t
b
e
e
n
c
h
a
r
a
c
t
e
r
i
z
e
d
.
A
l
l
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
s
h
o
u
l
d
b
e
c
o
n
s
i
d
e
r
e
d
a
b
s
e
n
t
p
e
n
d
i
n
g
P
h
a
s
e
3
a
n
d
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
s
t
u
d
y
p
u
b
l
i
c
a
t
i
o
n
.

Who should avoid it

Use outside of authorized clinical trials - no regulatory approval exists
Sourcing from unverified online vendors - no legitimate commercial supply exists for non-trial use
Combination with other amylin analogs (e.g., pramlintide) - no safety data for this combination
Use in pregnancy or lactation - no reproductive or developmental safety data available
Use in individuals with known calcitonin receptor-related conditions pending further characterization of CTR agonism effects
Assuming tolerability equivalence to GLP-1 agents without recognizing that Phase 3 safety data have not yet been published

How it is commonly combined

Roche's combination strategy pairs petrelintide with CT-388, a GLP-1/GIP dual agonist, as part of a co-development rationale premised on complementary mechanisms (amylin pathway plus incretin pathway) potentially producing additive weight loss with manageable tolerability. This combination approach is investigational and has not been evaluated in published human trials as of mid-2026. No evidence base supports other combinations for consumer use, and stacking with unapproved research compounds is not advisable outside of monitored clinical contexts.

Legal & regulatory. Investigational drug only. Not approved by the FDA, EMA, or any other regulatory authority as of mid-2026. No marketing authorization exists in any jurisdiction. Not for human consumption outside of authorized clinical trials. Classified as an unapproved investigational new drug (IND) under US law.

Quality & harm reduction

Safer, legal alternative we recommend

Big Berb Energy. For a natural approach to the same metabolic/blood-sugar goal, our Berberine is a well-studied legal supplement.

See our recommended pick

Find Petrelintide →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

How does petrelintide differ from semaglutide and other GLP-1 receptor agonists?

Petrelintide acts on amylin receptors and calcitonin receptors rather than the GLP-1 receptor. The proposed mechanism emphasizes restoration of leptin sensitivity and early satiation signaling rather than the incretin and gastric-emptying effects of GLP-1 agents. The Phase 2b tolerability data suggest substantially lower nausea and vomiting rates, though head-to-head trials have not been conducted and Phase 3 data are not yet available.

Has petrelintide been approved by the FDA?

No. As of mid-2026, petrelintide is an unapproved investigational drug with no regulatory marketing authorization in any jurisdiction. It is available only through authorized clinical trials.

What dose should I take?

This cannot be answered here. Petrelintide is not approved for use outside of clinical trials, and no dosing protocol is appropriate to provide for an investigational compound. Anyone with clinical interest in amylin-pathway therapies should speak with a licensed clinician.

What is the ZUPREME-1 trial and what did it find?

ZUPREME-1 (NCT06662539) was a Phase 2b trial enrolling adults with obesity or overweight without type 2 diabetes, running for 42 weeks. Top-line results announced in early 2026 reported 10.7% mean weight loss at the highest evaluated dose versus 1.7% for placebo, meeting the primary endpoint. Full peer-reviewed publication of detailed results had not been confirmed as of mid-2026.

Is petrelintide related to pramlintide (Symlin)?

Both are synthetic amylin analogs, but they differ substantially. Pramlintide is FDA-approved, short-acting, and requires multiple daily injections; it was developed as an adjunct to insulin in diabetes and achieves modest weight loss. Petrelintide is engineered for once-weekly dosing through acylation and lactam bridge stabilization, with an estimated half-life roughly 50-fold longer. They share the amylin receptor mechanism but are distinct compounds at different development stages.

Where can I buy petrelintide?

There is no legitimate commercial source. Petrelintide is an investigational compound with no approved formulation. Any product sold online as petrelintide or ZP8396 outside of clinical trials has unverified identity and purity and should not be used.

References & further reading

PubMed: Development of Petrelintide ZP8396 long-acting human amylin analogue Journal of Medicinal Chemistry PMID 41217931
ClinicalTrials.gov: NCT06662539 ZUPREME-1 Phase 2b petrelintide obesity overweight
ClinicalTrials.gov: NCT06926842 ZUPREME-2 Phase 2b petrelintide obesity type 2 diabetes
PubMed: amylin receptor agonist obesity weight loss leptin sensitivity satiation mechanism
PubMed: pramlintide amylin analog pharmacology calcitonin receptor RAMP